Ambrilia Biopharma
Ambrilia’s product portfolio includes: a sustained release octreotide formulation for treating acromegaly, a sustained release goserelin formulation for treating prostate cancer and other indications, HIV protease, integrase and entry inhibitors, HCV entry and polymerase inhibitors and Influenza A inhibitors.
